Reply

Reply

Show other versions (1)

Bibliographic Details
Main Authors:	Falk, R, Jennette, J, Gross, W, Guillevin, L, Hoffman, G, Jayne, D, Kallenberg, C, Luqmani, R, Mahr, A, Matteson, E, Specks, U, Merkel, P, Watts, R
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Reply.
by: Falk, R, et al.
Published: (2011)

Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis
by: Falk, R, et al.
Published: (2011)

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
by: Falk, R, et al.
Published: (2011)

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
by: Falk, R, et al.
Published: (2011)

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
by: Falk, R, et al.
Published: (2011)

Comparison of disease activity measures for ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2004)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
by: Merkel, P, et al.
Published: (2009)

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.
by: Jennette, J, et al.
Published: (2013)

2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
by: Jennette, J, et al.
Published: (2012)

The future of damage assessment in vasculitis.
by: Seo, P, et al.
Published: (2007)

Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.
by: Merkel, P, et al.
Published: (2005)

Reply
by: Grayson, PC, et al.
Published: (2022)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
by: Hellmich, B, et al.
Published: (2007)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
by: Walsh, M, et al.
Published: (2011)

EULAR recommendations for the management of primary small and medium vessel vasculitis.
by: Mukhtyar, C, et al.
Published: (2009)

EULAR recommendations for the management of large vessel vasculitis.
by: Mukhtyar, C, et al.
Published: (2009)

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
by: Mukhtyar, C, et al.
Published: (2008)

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis.
by: Basu, N, et al.
Published: (2010)

Eular recommendations for vasculitis
by: Luqmani, R, et al.
Published: (2007)

Outcome in systemic vasculitis.
by: Luqmani, R, et al.
Published: (1998)

Assessment of damage in vasculitis: expert ratings of damage.
by: Seo, P, et al.
Published: (2009)

Systemic vasculitis--is it time to reclassify?
by: Watts, R, et al.
Published: (2011)

Assessment of damage in vasculitis: Expert ratings of damage
by: Seo, P, et al.
Published: (2008)

Health-related quality of life in patients with ANCA-associated vasculitis: a pooled analysis of four randomized clinical trials
by: Walsh, M, et al.
Published: (2009)

Tumor necrosis factor-blocking agents in polymyalgia rheumatica and giant cell arteritis - Reply
by: Luqmani, R
Published: (2008)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
by: Lapraik, C, et al.
Published: (2007)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
by: Suppiah, R, et al.
Published: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
by: Suppiah, R, et al.
Published: (2011)

Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS).
by: Luqmani, R, et al.
Published: (2011)

Damage from Wegener's granulomatosis and its treatment: Prospective data from the Wegener's granulomatosis Etanercept Trial (WGET).
by: Seo, P, et al.
Published: (2004)

A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULOMATOSIS AND MICROSCOPIC POLYANGIITIS
by: Suppiah, R, et al.
Published: (2011)

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
by: Seo, P, et al.
Published: (2005)

Assessment of damage in vasculitis: expert ranking of items of damage
by: Seo, P, et al.
Published: (2007)

Global ethnic and geographic idfferences in the clinical features of ANCA-associated vasculitis
by: Pearce, F, et al.
Published: (2016)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
by: Pearce, F, et al.
Published: (2017)

The authors reply
by: Clatworthy, MR, et al.
Published: (2008)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.
by: Merkel, P, et al.
Published: (2009)

Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.
by: Mukhtyar, C, et al.
Published: (2007)

Pulmonary manifestations of primary systemic vasculitides
by: Makhzoum, J, et al.
Published: (2017)